News articles about IDEXX Laboratories (NASDAQ:IDXX) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.5592702519409 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
IDEXX Laboratories (NASDAQ:IDXX) traded up $1.35 during trading on Friday, hitting $156.60. 1,019,553 shares of the stock were exchanged, compared to its average volume of 696,988. IDEXX Laboratories has a 12-month low of $113.92 and a 12-month high of $173.01. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The company has a market cap of $13,798.00, a P/E ratio of 53.27, a PEG ratio of 2.39 and a beta of 0.42.
IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. During the same period in the previous year, the firm posted $0.62 EPS. The business’s quarterly revenue was up 9.7% on a year-over-year basis. sell-side analysts forecast that IDEXX Laboratories will post 3.24 earnings per share for the current year.
A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target on the stock in a report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. Canaccord Genuity restated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a report on Friday, October 6th. Finally, Bank of America upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price on the stock in a report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $173.67.
In related news, Chairman Jonathan W. Ayers sold 54,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the transaction, the chairman now directly owns 1,064,573 shares in the company, valued at approximately $161,091,186.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at $163,678,098.75. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock worth $16,686,200 over the last quarter. 2.77% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories (IDXX) Receiving Somewhat Favorable Press Coverage, Study Shows” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/15/idexx-laboratories-idxx-receiving-somewhat-favorable-press-coverage-study-shows.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.